BMT101 is our lead for the unmet ovarian cancer need

Ovarian cancer is an extremely deadly disease characterised by an abnormal growth of ovarian, fallopian tube or primary peritoneal tissue with malignant tumours spreading beyond the site of origin into the peritoneal cavity and affecting the organs within (e.g. the spleen, bowel mesentery and liver). There were 313,959 new cases of ovarian cancer worldwide in 2020 [GLOBOCAN] and it is the fifth leading cause of cancer deaths in women [ACS]. There haven't been major improvements in outcomes for close to half a century. Women diagnosed with ovarian cancer in 1975 experienced a five-year survival rate of 36% whereas the American Cancer Society estimates the rate to have only progressed to 49% by 2019. For most patients, surgery is the first line of treatment. This is usually followed by chemotherapy with typically devastating side effects including hair loss, nausea, vomiting, appetite loss, pain, weakened immunity and fatigue. There is a compelling patient need and large commercial opportunity for innovative therapies that significantly improve on chemotherapy efficacy and tolerability. BMT101 offers such an exciting new therapeutic approach.
Treated with chemotherapy
Survive over 10 years
Projected rise in incidence

Oncojans: Engineered cancer therapeutics

We are developing Oncojans, a promising new class of drug-loaded, long-acting particles, designed to precisely target and gain entry to cancer cells. In the tumours, they slowly release drugs at the point of need whilst sparing healthy tissue. Early preclinical studies for BMT101, our lead ovarian cancer candidate, compared to the clinical standard of care, paclitaxel, has shown very encouraging results including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, a 4-fold increase in survival and a reduction in toxicity. This includes work in immunocompetent models of advanced ovarian cancer disease.  BMT101 and future engineered Oncojans could be transformational in the treatment of cancer patients.
Increased efficacy
The targeted active therapeutic will deliver and sustain release drugs at tumours in order to prolong patient survival through efficacy gains.
Reduced toxicity
Less active therapeutic distributed or released at healthy tissues will significantly limit the side effects endured by patients.
More patients
Oncojans will enable more patients to be treated, including those that are frail and not currently able to tolerate standard chemotherapy regimens.

News

Team

Dr John beadle
Dr John beadle

Chairman

Dr John Beadle, MBBCh, MBA, brings a wealth of experience and knowledge in the development of clinical stage biotech companies. He was previously founding Chief Executive Officer of PsiOxus Therapeutics, founder and Chief Medical Officer of PowderMed, Entrepreneur-in-Residence at Imperial innovations, Site Head at Pfizer and Vice President of Global Medical Operations at GlaxoSmithKline. To date, he has raised in excess of $150M and realised transaction values in excess of $300M within the biotech industry.

Dr Davidson Ateh
Dr Davidson Ateh

Founder and CEO

Davidson is an entrepreneurial bioengineer with a successful track record of managing and financing disruptive early stage technology projects. He has an interdisciplinary background in the physical and life sciences with a BEng in Biomedical Materials and a PhD in Bioengineering from Queen Mary University of London. He was a recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship during which he had a year of business training at the endowed Hunter Centre for Entrepreneurship of Strathclyde Business School. He has raised over $3.5M in non-dilutive and risk capital. He has secured a number of alliances and progressed BioMoti’s innovative Oncojan cancer therapeutics platform towards clinical development.

Prof Joanne Martin
Prof Joanne Martin

Founder and NED

Jo is Professor of Pathology, Deputy Vice Principal Health and Director of the Blizard Institute at Queen Mary University of London. She is also Consultant Histopathologist at Barts Health NHS Trust and National Specialty Advisor for Pathology at NHS England. She was previously the President of The Royal College of Pathologists. Jo has an international reputation in the study of diseases with over 125 publications including high impact journals such as Science and Nature. She is an experienced business leader (MA in Leadership) with a track record of running a large NHS Trust Division (£89 million budget per annum), delivering and commissioning a £40 million building, and 2 major IT system implementations.

Get in touch

The QMB Innovation Centre | 42 New Road London E1 2AX | UK